Biotest Aktiengesellschaft (BIESF)
USD 32.0
(0.0%)
USD 32.0
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 614.1 Million EUR | 6.93% |
| 2022 | 574.3 Million EUR | 15.72% |
| 2021 | 496.3 Million EUR | 5.8% |
| 2020 | 469.1 Million EUR | 14.53% |
| 2019 | 409.6 Million EUR | 24.35% |
| 2018 | 329.4 Million EUR | -18.95% |
| 2017 | 406.4 Million EUR | 17.39% |
| 2016 | 346.2 Million EUR | 0.46% |
| 2015 | 344.6 Million EUR | 3.83% |
| 2014 | 331.9 Million EUR | 43.37% |
| 2013 | 231.5 Million EUR | 105.82% |
| 2012 | 112.47 Million EUR | -19.1% |
| 2011 | 139.03 Million EUR | 0.0% |
| 2010 | - EUR | 0.0% |
| 2009 | - EUR | 0.0% |
| 2008 | - EUR | 0.0% |
| 2007 | - EUR | 0.0% |
| 2006 | - EUR | 0.0% |
| 2005 | - EUR | 0.0% |
| 2004 | - EUR | 0.0% |
| 2003 | - EUR | 0.0% |
| 2002 | - EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 624.3 Million EUR | -9.94% |
| 2024 Q1 | 693.2 Million EUR | 12.88% |
| 2023 Q2 | 662.1 Million EUR | 1.72% |
| 2023 Q3 | 695.8 Million EUR | 5.09% |
| 2023 FY | 614.1 Million EUR | 6.93% |
| 2023 Q4 | 614.1 Million EUR | -11.74% |
| 2023 Q1 | 650.9 Million EUR | 13.34% |
| 2022 FY | 574.3 Million EUR | 15.72% |
| 2022 Q3 | 546.3 Million EUR | 1.2% |
| 2022 Q2 | 539.8 Million EUR | 1.09% |
| 2022 Q4 | 574.3 Million EUR | 5.13% |
| 2022 Q1 | 534 Million EUR | 7.6% |
| 2021 Q1 | 472.2 Million EUR | 0.66% |
| 2021 FY | 496.3 Million EUR | 5.8% |
| 2021 Q2 | 498.59 Million EUR | 5.59% |
| 2021 Q3 | 505.1 Million EUR | 1.3% |
| 2021 Q4 | 496.3 Million EUR | -1.74% |
| 2020 Q2 | 467.3 Million EUR | 13.48% |
| 2020 Q1 | 411.8 Million EUR | 0.54% |
| 2020 Q3 | 468.4 Million EUR | 0.24% |
| 2020 Q4 | 469.1 Million EUR | 0.15% |
| 2020 FY | 469.1 Million EUR | 14.53% |
| 2019 Q2 | 354.8 Million EUR | 0.6% |
| 2019 FY | 409.6 Million EUR | 24.35% |
| 2019 Q4 | 409.6 Million EUR | -0.27% |
| 2019 Q3 | 410.7 Million EUR | 15.76% |
| 2019 Q1 | 352.7 Million EUR | 7.07% |
| 2018 FY | 329.4 Million EUR | -18.95% |
| 2018 Q4 | 329.4 Million EUR | -6.71% |
| 2018 Q2 | 615.5 Million EUR | 30.6% |
| 2018 Q1 | 471.3 Million EUR | 15.97% |
| 2018 Q3 | 353.1 Million EUR | -42.63% |
| 2017 Q3 | 412.4 Million EUR | -0.46% |
| 2017 Q2 | 414.3 Million EUR | 18.2% |
| 2017 Q4 | 406.4 Million EUR | -1.45% |
| 2017 Q1 | 350.5 Million EUR | 1.24% |
| 2017 FY | 406.4 Million EUR | 17.39% |
| 2016 Q1 | 349.2 Million EUR | 1.33% |
| 2016 Q3 | 347.8 Million EUR | -0.51% |
| 2016 FY | 346.2 Million EUR | 0.46% |
| 2016 Q4 | 346.2 Million EUR | -0.46% |
| 2016 Q2 | 349.6 Million EUR | 0.11% |
| 2015 Q3 | 347.2 Million EUR | -0.34% |
| 2015 FY | 344.6 Million EUR | 3.83% |
| 2015 Q4 | 344.6 Million EUR | -0.75% |
| 2015 Q2 | 348.4 Million EUR | 1.16% |
| 2015 Q1 | 344.4 Million EUR | 3.77% |
| 2014 Q2 | 246.7 Million EUR | 0.24% |
| 2014 Q3 | 249.1 Million EUR | 0.97% |
| 2014 Q4 | 331.9 Million EUR | 33.24% |
| 2014 FY | 331.9 Million EUR | 43.37% |
| 2014 Q1 | 246.1 Million EUR | 6.31% |
| 2013 Q3 | 98.1 Million EUR | -4.39% |
| 2013 Q4 | 231.5 Million EUR | 135.98% |
| 2013 FY | 231.5 Million EUR | 105.82% |
| 2013 Q1 | 32.4 Million EUR | -71.19% |
| 2013 Q2 | 102.6 Million EUR | 216.67% |
| 2012 FY | 112.47 Million EUR | -19.1% |
| 2012 Q3 | - EUR | 0.0% |
| 2012 Q4 | 112.47 Million EUR | 0.0% |
| 2012 Q1 | - EUR | -100.0% |
| 2012 Q2 | - EUR | 0.0% |
| 2011 Q1 | - EUR | 0.0% |
| 2011 Q4 | 139.03 Million EUR | 0.0% |
| 2011 FY | 139.03 Million EUR | 0.0% |
| 2011 Q2 | - EUR | 0.0% |
| 2011 Q3 | - EUR | 0.0% |
| 2010 Q4 | - EUR | 0.0% |
| 2010 Q3 | - EUR | 0.0% |
| 2010 Q2 | - EUR | 0.0% |
| 2010 FY | - EUR | 0.0% |
| 2010 Q1 | - EUR | 0.0% |
| 2009 FY | - EUR | 0.0% |
| 2009 Q4 | - EUR | 0.0% |
| 2008 FY | - EUR | 0.0% |
| 2007 FY | - EUR | 0.0% |
| 2006 FY | - EUR | 0.0% |
| 2005 FY | - EUR | 0.0% |
| 2004 FY | - EUR | 0.0% |
| 2003 FY | - EUR | 0.0% |
| 2002 FY | - EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Bioxytran, Inc. | 1.92 Million USD | -31801.299% |
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | -1390.425% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -152718.596% |
| SQZ Biotechnologies Company | 27.47 Million USD | -2135.448% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -26302.059% |
| Evofem Biosciences, Inc. | 43.37 Million USD | -1315.858% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | -1963.013% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -64659.968% |
| Marizyme, Inc. | 18.71 Million USD | -3180.888% |
| Genus plc | 233.1 Million USD | -163.449% |
| Pharming Group N.V. | 171.54 Million USD | -257.982% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -69050.422% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -45606.111% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -81780.0% |
| ContraFect Corporation | 2.88 Million USD | -21215.515% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -42359.513% |
| IMV Inc. | 28.88 Million USD | -2026.098% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | -10752.981% |
| ONE Bio Corp. | 19.71 Million USD | -3014.884% |
| RVL Pharmaceuticals plc | 57.48 Million USD | -968.204% |
| Mesoblast Limited | 118.7 Million USD | -417.353% |
| MultiCell Technologies, Inc. | 202.58 USD | -303139400.444% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | -1755.231% |
| Genscript Biotech Corporation | 417.73 Million USD | -47.006% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -97364.278% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -49893.447% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -14798.263% |
| Biomind Labs Inc. | 735.54 Thousand USD | -83389.454% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -20192.837% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | -4624.938% |
| Skye Bioscience, Inc. | 4.61 Million USD | -13205.842% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -170620.858% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -20856.269% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -433837.732% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -453153.818% |
| Arch Therapeutics, Inc. | 5.87 Million USD | -10359.727% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -2387628.916% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.49 Million USD | -40983.766% |
| Q BioMed Inc. | 4.1 Million USD | -14841.675% |
| GB Sciences, Inc. | 1.75 Million USD | -34805.79% |
| Alpha Cognition Inc. | 1.22 Million USD | -50220.722% |
| CSL Limited | 12.18 Billion USD | 94.959% |
| Agentix Corp. | 50 Thousand USD | -1228100.0% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | -807.856% |
| Enzolytics Inc. | 996.33 Thousand USD | -61535.71% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | 6.49 Million USD | -9360.792% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -240165.736% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -27092.046% |
| argenx SE | 20 Million USD | -2970.5% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | -1247.893% |
| HST Global, Inc. | 98.31 Thousand USD | -624499.518% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -246804.149% |
| Halberd Corporation | 150 Thousand USD | -409300.0% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -8582.546% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -6005767.971% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -22571.367% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -25511.789% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -267725.602% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -413006.946% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -306007.19% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.19 Million USD | -27815.159% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | -2920.956% |
| Kadimastem Ltd | 891.22 Thousand USD | -68805.081% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 4.71 Million USD | -12934.295% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -245361.304% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| LadRx Corporation | 33.6 Thousand USD | -1827252.259% |
| Cell Source, Inc. | 9.25 Million USD | -6535.925% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -81108.245% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -81108.245% |
| Affymax, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -126705.759% |
| Itoco Inc. | 228.37 Thousand USD | -268797.481% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -290977.142% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -12223.901% |
| International Stem Cell Corporation | 4.17 Million USD | -14598.42% |
| CytoDyn Inc. | 30.07 Million USD | -1941.827% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -174436.091% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -7752.981% |
| SYBLEU INC | 477.5 Thousand USD | -128507.33% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -501206.122% |
| Rebus Holdings, Inc. | 310 Thousand USD | -197996.774% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -12868.605% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -983829.63% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -28058.1% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | -7284.56% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | -7053.174% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -39379.8% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -229041.791% |
| Neutra Corp. | 54.15 Thousand USD | -1133846.377% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -33457.377% |
| PureTech Health plc | 25.51 Million USD | -2307.103% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -50062.307% |
| IXICO plc | 472.02 Thousand USD | -129999.593% |
| IntelGenx Technologies Corp. | 15.5 Million USD | -3861.68% |
| Gelesis Holdings, Inc. | 62.26 Million USD | -886.3% |
| CSL Limited | 12.18 Billion USD | 94.959% |
| Cellectis S.A. | 92.77 Million USD | -561.913% |